WHO panel gives nod to AstraZeneca Covid-19 vaccine, has "tremendous potential"

"The AstraZeneca Covid-19 vaccine (including Covishield) continues to have a positive benefit-risk profile, with tremendous potential to prevent infections and reduce deaths across the world," the WHO's global advisory committee on vaccine safety said.

The World Health Organization's vaccine safety panel said on Friday that data from AstraZeneca's Covid-19 shot do not point to any overall increase in clotting conditions but it would continue to monitor its effects.

Indonesia had previously delayed administering the AstraZeneca vaccine following the blood clot reports. (Reuters)

"The AstraZeneca Covid-19 vaccine (including Covishield) continues to have a positive benefit-risk profile, with tremendous potential to prevent infections and reduce deaths across the world," the WHO's global advisory committee on vaccine safety said in a statement issued after its independent experts met on Tuesday and on Thursday to review data.